Management of Acheminall Corporationare focused on schistosomiasis, a significant, unmet medical need in 78 endemic countries, with more than 200 million people infected, 20 million with significant morbidity, and more than 200,000 deaths annually. Current schistosomiasis control strategies rely almost exclusively on chemotherapy; there is only one available drug and it is inevitable that drug-resistant parasites will evolve. The proposed research will exploit differences in redox defenses between schistosome worms and humans to discover and optimize small molecule inhibitors to selectively disrupt worm redox for new treatments for schistosomiasis.
